News on NGS technologies, RNA-seq, clinical sequencing, & sample prep in genetics, genomics, and molecular diagnostics.
Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.
The companies will pair sequencing with genotype-phenotype matching and analytics in pursuit of wider access to precision medicine and faster, more accurate diagnoses.
The company plans to take a tiered approach to assay development, targeting its first test to 10 viruses commonly detected in transplant patients.
The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.
While the company's product and product-related revenues rose 54 percent, its collaborative development program revenues fell 78 percent.
